{"id":"NCT02436668","sponsor":"Pharmacyclics LLC.","briefTitle":"Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)","officialTitle":"A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2018-10","completion":"2019-04-25","firstPosted":"2015-05-07","resultsPosted":"2020-11-16","lastUpdate":"2020-12-30"},"enrollment":430,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Pancreatic Adenocarcinoma"],"interventions":[{"type":"DRUG","name":"Ibrutinib","otherNames":["IMBRUVICAÂ®"]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Nab-paclitaxel","otherNames":[]}],"arms":[{"label":"Ibrutinib","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Results at an overall median follow-up of 24.87 months","effectByArm":[{"arm":"Ibrutinib+Gemcitabine+Nab-paclitaxel","deltaMin":5.32,"sd":null},{"arm":"Placebo+Gemcitabine+Nab-Paclitaxel","deltaMin":6.01,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":86,"countries":["United States","Belgium","France","Germany","Italy","South Korea","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":127,"n":212},"commonTop":["Diarrhoea","Nausea","Asthenia","Anaemia","Alopecia"]}}